Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary aim of this study is to evaluate the efficacy and tolerability of a combined Virtual Reality (VR)-based mindfulness intervention and pharmacological treatment compared with pharmacological treatment alone in reducing depressive symptoms in patients with Treatment-Resistant Depression (TRD). Secondary questions this study aims to address include: 1. Does the combined intervention lead to changes in inflammatory blood parameters compared with pharmacological treatment alone? 2. Does the addition of a VR-based mindfulness intervention prolong remission of depressive symptoms six months after treatment completion? 3. Is the combined treatment with mindfulness and esketamine well-tolerated, and how does its adverse effect profile compare with esketamine treatment alone? 4. Is there an association between changes in mindfulness trait levels, assessed using the FFMQ-SF, and reductions in depressive symptom severity? Participants will be recruited from a Treatment-Resistant Depression Programme and randomly assigned to receive either VR-based mindfulness intervention in addition to treatment as usual or treatment as usual alone. The mindfulness intervention will last one month and include a total of 8 sessions. All participants will undergo comprehensive assessments at baseline and at predefined follow-up time points to evaluate clinical outcomes, inflammatory markers, tolerability, and remission duration.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Virtual-Reality-based mindfulness intervention — The mindfulness-based intervention will be delivered using a virtual reality (VR) platform (Sunrise Serenity) developed by XRHealth. The intervention consists of a 10-minute guided mindfulness meditation presented in a 360-degree immersive virtual environment depicting a seaside scene at sunrise. Participants will use a Pico Neo 2 VR headset with handheld controllers. The intervention software will be pre-installed on the device to ensure standardised delivery. Prior to the first intervention session, participants will complete a 5-minute familiarisation period with the VR equipment to ensure comfort and proper use. The VR-based mindfulness session will be administered immediately before each intranasal esketamine treatment during the induction phase (weeks 1-4; 8 sessions in total). The software used is patented and certified for medical use, with regulatory approval from the U.S. Food and Drug Administration (FDA) and CE marking.
  • Drug: Esketamine Treatment as Usual (ESK) — The treatment with intranasal esketamine for treatment-resistant depression includes two phases. Induction Phase (Weeks 1-4): Following diagnosis of treatment-resistant depression, participants will receive intranasal esketamine twice weekly for four weeks. At the first treatment session, a total dose of 56 mg (two 28 mg devices) will be administered. In subsequent sessions, the dose may be adjusted according to individual tolerability and clinical judgement. Maintenance Phase (Weeks 5-30): After completion of the induction phase, participants will enter a maintenance phase in which esketamine will be administered once weekly for four weeks, followed by administration once every two weeks until the end of the treatment period. Doses of 56 mg or 84 mg will be administered based on clinical response and tolerability, with dose adjustments made according to clinical evolution.

Primary Outcomes

  • Severity in depressive symptoms as assessed by Montgomery-Åsberg Depression Rating Scale (MADRS) (Baseline (Week 0), Week 4 (end of the induction phase), Week 30 (end of the maintenance phase), and Week 54 (follow-up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-18
Completion: 2026-12-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Contact Information
Study Contact:
Dr. J. Antoni Ramos-Quiroga
+3493 274 6087
antoni.ramos@vallhebron.cat
Júlia Vendrell-Serres
+3493 274 60 87
julia.vendrell@vallhebron.cat
Dr. J. Antoni Ramos-Quiroga
+3493 274 6087
antoni.ramos@vallhebron.cat
Hospital Universitari Vall d'Hebron
Interventions
  • Behavioral: Virtual-Reality-based mindfulness intervention — The mindfulness-based intervention will be delivered using a virtual reality (VR) platform (Sunrise Serenity) developed by XRHealth. The intervention consists of a 10-minute guided mindfulness meditation presented in a 360-degree immersive virtual environment depicting a seaside scene at sunrise. Participants will use a Pico Neo 2 VR headset with handheld controllers. The intervention software will be pre-installed on the device to ensure standardised delivery. Prior to the first intervention session, participants will complete a 5-minute familiarisation period with the VR equipment to ensure comfort and proper use. The VR-based mindfulness session will be administered immediately before each intranasal esketamine treatment during the induction phase (weeks 1-4; 8 sessions in total). The software used is patented and certified for medical use, with regulatory approval from the U.S. Food and Drug Administration (FDA) and CE marking.
  • Drug: Esketamine Treatment as Usual (ESK) — The treatment with intranasal esketamine for treatment-resistant depression includes two phases. Induction Phase (Weeks 1-4): Following diagnosis of treatment-resistant depression, participants will receive intranasal esketamine twice weekly for four weeks. At the first treatment session, a total dose of 56 mg (two 28 mg devices) will be administered. In subsequent sessions, the dose may be adjusted according to individual tolerability and clinical judgement. Maintenance Phase (Weeks 5-30): After completion of the induction phase, participants will enter a maintenance phase in which esketamine will be administered once weekly for four weeks, followed by administration once every two weeks until the end of the treatment period. Doses of 56 mg or 84 mg will be administered based on clinical response and tolerability, with dose adjustments made according to clinical evolution.
Study Locations (1 sites)
Hospital Universitari Vall d'Hebron, Barcelona, 08035 Spain
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 74 years, inclusive * Diagnosis of treatment-resistant Major Depressive Disorder (MDD), single or recurrent episode, in accordance with DSM-5 diagnostic criteria. * Inadequate response to two or more oral antidepressants during the current depressive episode * Inadequate response to at least one pharmacological combination or augmentation strategy * Ability and willingness to provide written informed consent for participation and data collection Exclusion Criteria: * Presence of any contraindication to esketamine administration according to the approved product label * Current participation in another interventional clinical study involving antidepressant medication * Any medical, psychiatric, or other condition that, in the opinion of the investigator, could: (a) compromise participant safety or well-being, or (b) interfere with, limit, or confound study assessments or outcomes
Conditions Asthma Attack, Asthma Control, Asthma Ex...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is testing a new way to help adults with asthma get follow up care after an emergency room (ER) visit for an asthma attack. Many people who come to the ER for asthma never see an asthma specialist afterward, even though specialists can offer treatments such as advanced inhalers or biologic medicines that may prevent future attacks. The study will compare two approaches. One group will receive a telehealth appointment with an asthma specialist that is scheduled for them before they leave the ER. The other group will receive the usual care, which typically includes a standard referral but no scheduled appointment. All participants will be offered a prescription for standard controller medication at discharge. The main question the study aims to answer is whether arranging a telehealth visit directly from the ER increases the number of patients who complete a follow up appointment with an asthma specialist within three months. The study will also look at whether this approach improves asthma control, reduces repeat ER visits, and helps patients better understand and use their asthma medications. This research may help identify a practical way to improve access to asthma specialists and reduce the burden of asthma for patients who frequently rely on emergency care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: ER-Initiated Telehealth Referral — Participants assigned to the intervention arm will receive an asthma specialist follow up appointment that is scheduled directly from the emergency department before discharge. Emergency department staff will contact the specialist clinic to arrange a telehealth visit within 1-3 weeks. The telehealth visit will address asthma symptoms, medication use, and follow-up care needs. All participants, including those in the intervention arm, will be offered a prescription for standard inhaled corticosteroid/long-acting beta-agonist controller therapy at discharge. The intervention focuses on improving access to specialist care through proactive scheduling and telehealth delivery.

Primary Outcomes

  • Proportion of Participants Completing an Asthma Specialist Follow-Up Visit Within 3 Months After Emergency Department Discharge (Within 3 months after emergency department discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-19
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Juan Carlos Cardet
Collaborators: Tampa General Hospital, University of South Florida, Sanofi
Principal Investigators:
  • Juan C Cardet, MD (PRINCIPAL_INVESTIGATOR) - University of South Florida
Contact Information
Study Contact:
Amanda McNamara, BA, LPN
813-396-2729
Alett1@usf.edu
Hope Brunner, RN, BSN
813-844-7289
hbrunner@tgh.org
Tampa General Hospital Emergency Room
Interventions
  • Behavioral: ER-Initiated Telehealth Referral — Participants assigned to the intervention arm will receive an asthma specialist follow up appointment that is scheduled directly from the emergency department before discharge. Emergency department staff will contact the specialist clinic to arrange a telehealth visit within 1-3 weeks. The telehealth visit will address asthma symptoms, medication use, and follow-up care needs. All participants, including those in the intervention arm, will be offered a prescription for standard inhaled corticosteroid/long-acting beta-agonist controller therapy at discharge. The intervention focuses on improving access to specialist care through proactive scheduling and telehealth delivery.
Study Locations (1 sites)
Tampa General Hospital Emergency Room, Tampa, Florida 33606 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Asthma diagnosis ≥1 year * Seen in ER for asthma exacerbation * Persistent asthma on controller therapy * ≥1 asthma exacerbation in prior year Exclusion Criteria: * Patients who have seen an asthma specialist (allergist or pulmonologist) for asthma in the past 1 year * Diagnosis of other pulmonary diseases (e.g., COPD, interstitial lung disease, etc.) We will allow for current smokers, vapers and cannabis users as long as they meet one of the COPD-allowable pathways below. COPD-allowable pathways: If none of the below are satisfied, then exclude for COPD. Documentation: PFTs must be within 36 months of enrollment date; smoking history must be calculated and entered in this form based on patient input. Pack- year history will be collected for characterization/analysis but will not determineeligibility. We will allow for COPD as long as they are: * never smokers/vapers/cannabis users; * former or current smokers/vapers/cannabis users with normal PFTs with FEV1/FVC \>=70% documented in a medical record within 36 months of the enrollment date * former or current smoker/vapers/cannabis users with obstruction noted on PFTs (i.e., FEV1/FVC \<70%) but who demonstrates BOTH acute bronchodilator reversibility (i.e., \>10% increase in either FEV1%predicted or FVC% predicted) AND have a normal diffusing capacity (DLCO)
Conditions Hypertension
Phase NA
Enrollment 480
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The proposed study, "Check, Monitor, Control Hypertension in Older African American Adults," is a randomized clinical trial designed to improve blood pressure control among African American adults aged 55 years and older in the Greater Houston area. Hypertension disproportionately affects African Americans, contributing to higher rates of cardiovascular disease and stroke. This project aims to improve clinical and behavioral outcomes through a 24-month intervention combining pharmacist-led counseling and Community Health Worker (CHW) support.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Pharmacists Only (Control Group) — Medication management and disease state counseling provided by a clinical pharmacist.
  • Other: Combined Intervention (Pharmacists + CHW Interventions) — Participants receive CHW Individual patient assistance and group health workshops in addition to pharmacist interventions

Primary Outcomes

  • Change in Systolic Blood Pressure (Baseline, 6 months, 12 months, 18 months, 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2030-05-31
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 480 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Texas Southern University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Ivy O Poon, Pharm.D., M.S., BCPS (PRINCIPAL_INVESTIGATOR) - Texas Southern University
Contact Information
Study Contact:
Ivy 0 Poon, Pharm.D., M.S., BCPS
713-313-4400
ivy.poon@tsu.edu
Creaque C Tyler, PharmD, BCGP
creaque.charles@tsu.edu
Ivy 0 Poon, Pharm.D., M.S., BCPS
713-313-4400
ivy.poon@tsu.edu
3100 Cleburne Street, Nabrit Science Building,
Interventions
  • Other: Pharmacists Only (Control Group) — Medication management and disease state counseling provided by a clinical pharmacist.
  • Other: Combined Intervention (Pharmacists + CHW Interventions) — Participants receive CHW Individual patient assistance and group health workshops in addition to pharmacist interventions
Study Locations (1 sites)
3100 Cleburne Street, Nabrit Science Building,, Houston, Texas 77004 United States
Eligibility Criteria
Inclusion Criteria: Individuals are eligible to the study if they are: * 55 years or older * Have at least 2 high blood pressure readings ≥ 130/80 mmHg within one month * Past Medical History of hypertension \> 1 year * Taking at least 1 antihypertensive medication * Independent Activities of Daily Livings (ADL) and instrumental Activities of Daily Livings (iADL) * Have a SmartPhone * Live within the Greater Houston Metropolitan Areas * Able to speak English Exclusion criteria: * Unable to verbalize comprehension of study or impaired cognitive function (e.g. dementia) * Not able to monitor blood pressure at home * Plans to relocate outside Houston within the next year
Conditions Obesity&T2D
Phase PHASE1
Enrollment 138
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, randomized, single-dose, parallel comparison bioequivalence study conducted in healthy adult male subjects. The study is divided into 3 parts, each of which evaluates the bioequivalence of GZR18 Injection for one strength before and after CMC changes. Subjects eligible for each part of the screening will be randomized into Group A or Group B in a 1:1 ratio. Each subject will receive a single dose of GZR18 Injection, followed by PK blood sampling and safety follow-up for 35 days. Subjects will be admitted to the hospital 1 day predose, follow a standardized light diet that evening, and then fast for at least 10 h thereafter. On the day of administration, GZR18 Injection of a single strength will be administered subcutaneously under fasting conditions at a site approximately two finger-widths (2.5 cm) away from the umbilicus on the abdomen. Lunch and dinner will be served approximately 3 and 9 h postdose, respectively. Venous blood will be collected at 14 time points for GZR18 plasma concentration analysis: at 0 h (within 60 min predose) and 1, 6, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672, and 840 h postdose. Subjects will undergo corresponding laboratory safety tests at screening, D36, and early withdrawal visits. During the entire study period, subjects should maintain a light diet, avoid strenuous exercise, and refrain from consuming juice, caffeinated beverages (such as tea and coffee), and alcoholic drinks. Smoking and any other activities that may affect PK observation or safety evaluations are strictly prohibited.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: GZR18 injection A — Administered SC
  • Drug: GZR18 injection B — Single dose, s.c.

Primary Outcomes

  • the maximum concentration (Cmax) (Day1-Day36)
  • the area under the concentration-time curve during a dosing interval (AUC0-t) (Day1-Day36)
  • the area under the concentration-time curve from the time of dosing extrapolated to infinity (AUC0-∞) (Day1-Day36)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-01-09
Completion: 2026-05-20
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: true
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gan & Lee Pharmaceuticals.
Contact Information
Study Contact:
Xin Zhang Xin Zhang
010-56456739
xin5.zhang@ganlee.com
Xin Zhang Xin Zhang
010-56456739
xin5.zhang@ganlee.com
The Second Affiliated Hospital of Soochow University
Interventions
  • Drug: GZR18 injection A — Administered SC
  • Drug: GZR18 injection B — Single dose, s.c.
Study Locations (1 sites)
The Second Affiliated Hospital of Soochow University, Suzhou, Suzhou China
Eligibility Criteria
Inclusion Criteria: 1. Subjects who voluntarily sign the Informed Consent Form (ICF), can receive SC injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on contraindications and restrictions specified in this protocol. 2. Male, 18 to 50 years of age at signing the ICF (both inclusive). 3. Weight ≥ 50 kg and body mass index (BMI) within 19-26 kg/m2 (inclusive) at screening. 4. Subjects of childbearing potential with no birth plan from the signing of ICF to 8 weeks after the last dose, willingness to take effective contraceptive measures, and no plan for sperm donation. \- Exclusion Criteria: 1. Subjects with clinically significant abnormalities detected during the screening period in physical examination, vital signs, laboratory tests, 12-lead ECG, abdominal ultrasound, or chest X-ray, as determined by the investigator. 2. Subjects who test positive for hepatitis B virus surface antigen, hepatitis C virus IgG antibody, human immunodeficiency virus antibody, P24 antigen, or anti-treponema pallidum antibody. 3. Subjects with a history of or existing circulatory, urinary, digestive, respiratory, nervous, endocrine, or psychiatric disorders that, in the investigator's judgment, remain clinically significant. 4. History of acute or chronic pancreatitis and pancreatic injury before screening. 5. History or family history of previous or existing medullary thyroid carcinoma, multiple endocrine neoplasia type 2. 6. Subjects who have used any drugs that alter the activity of drug metabolizing enzymes or transporters within 4 weeks prior to screening, or subjects with acute diseases or concomitant medication from the screening period to before randomization. 7. Subjects with severe infection or unexplained infection within 4 weeks before screening. 8. Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study. 9. Subjects known or suspected to have hypersensitivity to any ingredient of the investigational medicinal product (IMP) (glucagon like peptide-1 receptor agonist (GLP-1RA) or its excipients). 10. Use of any prescription drugs, over-the-counter drugs or Chinese herbal medicine within 2 weeks prior to screening; use of any GLP-1R agonists or drugs with the same mechanism of action to GLP-1R agonists (such as GLP-1R/glucagon receptor \[GCGR\] agonists or gastric inhibitory polypeptide receptor \[GIPR\]/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists) within 3 months prior to screening. 11. Subjects who have been vaccinated within 1 month before screening or are scheduled for vaccination during the study. 12. Blood donation or blood loss greater than or equal to 400 mL within 3 months before screening, or blood donation scheduled during the study or within 8 weeks after the end of the study. 13. History of drug abuse prior to screening; or positive results for drug abuse at screening (D-1). 14. History of alcohol abuse within 3 months prior to screening, defined as an average intake of more than 14 units per week (1 standard unit=360 mL of beer or 150 mL of 12% wine or 45 mL of 40% spirits); or use of any alcohol-containing products 48 hours before administration; or abnormal results for breath alcohol test at screening (D-1). 15. Subjects who smoked more than 5 cigarettes per day on average within the 3 months before screening, or who do not agree to abstain from smoking for the duration of the study. 16. Subjects who engage in strenuous exercise within 48 h before administration of the IMP, or have other factors that may affect drug absorption, distribution, metabolism, or excretion. 17. Subjects who consume grapefruit or grapefruit-containing products, or any caffeinated or xanthine-containing foods or beverages (such as coffee, tea, cola, or chocolate) within 48 hours before administration of the IMP. 18. Subjects who have special dietary requirements and cannot adhere to a standardized diet, or who are lactose intolerant. 19. Subjects with a history of needle phobia and blood phobia, difficulty in blood collection or intolerance to venous blood collection. 20. Subjects who are investigators or employees of the study site, or family members of the employees or investigators. 21. Participation in a clinical study of another IMP or device within 3 months before screening, or within 5 half-lives of the previous IMP (whichever is longer). Or plan to participate in another clinical study of an IMP or device before completing all scheduled assessments in the clinical study. \-
Conditions Breast Cancer, Old Age
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is one of the tumors with the highest incidence and current evidence indicates a higher prevalence in elderly patients (≥70 years) with a higher mortality rate due to immunosenescence, diagnostic delay and under treatment. Elderly patients are still poorly represented in clinical trials and the main indications for the treatment of the elderly population are extrapolated from the guidelines used in studies conducted predominantly on the younger population. In particular, these guidelines do not take into account the significant variability of elderly patients, in particular their comorbidities, performance status, physiological age and frailty. The aim of this study is to improve understanding of the clinical efficacy and safety of CDK 4/6i in older women in a real-world setting compared to younger women.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Evaluate the toxicity rate (both hematological and non-hematological) of any severity level in elderly patients (≥70 years) during administration of CDK 4/6i. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-21
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Contact Information
Study Contact:
Angioletta Lasagna
+39 0382502523
a.lasagna@smatteo.pv.it
Fondazione IRCCS Policlinico San Matteo di Pavia
comitato.bioetica@smatteo.pv.it
Fondazione IRCCS Policlinico San Matteo di Pavia
Interventions
N/A
Study Locations (1 sites)
Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Pavia 27100 Italy
Eligibility Criteria
Inclusion Criteria: * age over 18 years * patients with solid tumours undergoing active systemic treatment with CDK4/6 for adjuvant disease Exclusion Criteria: * Patients who are unable to understand informed consent document
Conditions Intracranial Hypertension
Phase Not Applicable
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective study aims to compare the effects of minimal invasive extracorporeal circulation (MiECC) and conventional reservoir-based extracorporeal circulation techniques on cerebral perfusion in patients undergoing elective coronary artery bypass graft (CABG) surgery. Although the adverse effects of cardiopulmonary bypass on cerebral perfusion and oxygenation are well recognized, the relationship between these effects and changes in intracranial pressure has not been fully elucidated. In this context, ultrasonographic measurement of optic nerve sheath diameter (ONSD), a non-invasive surrogate marker of intracranial pressure, will be used in combination with near-infrared spectroscopy (NIRS) to enable a comprehensive assessment of cerebral perfusion and oxygenation. Between February 2026 and February 2027, a total of 70 ASA II-III patients scheduled for elective CABG surgery will be prospectively enrolled and allocated according to the extracorporeal circulation technique used. Perioperative ONSD measurements will be performed by a single anesthesiologist blinded to the perfusion technique. The primary endpoint is the comparison of perioperative changes in ONSD between the two techniques. Secondary endpoints include the correlation between ONSD and NIRS values, incidence of cerebrovascular events, extubation time, duration of intensive care unit and hospital stay, perioperative hemodynamic parameters, and postoperative complications. This study is expected to provide clinically relevant data on the cerebral effects of different extracorporeal circulation strategies and contribute to perioperative neuromonitoring practices in cardiac surgery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Perioperative Optic Nerve Sheath Diameter (ONSD) (Before initiation of cardiopulmonary bypass (CPB), during CPB, and immediately after completion of CPB (within the intraoperative period).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-01
Completion: 2027-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kartal Kosuyolu High Speciality Training and Research Hospital
Principal Investigators:
  • Mustafa Burgaç (PRINCIPAL_INVESTIGATOR) - mustafaburgac@outlook.com
Contact Information
Study Contact:
Mustafa Burgaç, himself
0 538 984 8198
mustafaburgac@gmail.com
Mustafa Burgaç
05389848198
mustafaburgac@gmail.com
Mustafa Burgaç
05389848198
mustafaburgac@gmail.com
Kosuyolu High Specialization Training and Research Hospital
Interventions
N/A
Study Locations (1 sites)
Kosuyolu High Specialization Training and Research Hospital, Istanbul, 34870 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Scheduled for elective coronary artery bypass graft (CABG) surgery * American Society of Anesthesiologists (ASA) physical status II-III * Planned use of extracorporeal circulation during surgery * Ability to provide written informed consent Exclusion Criteria: * Age \< 18 years * ASA physical status other than II-III * Emergency surgery * Pregnancy * History of neurological disease affecting consciousness or decision-making capacity * History of psychiatric disease affecting decision-making capacity * History of head trauma within the previous 24 hours * Presence of carotid artery stenosis or significant carotid artery disease * Coagulation disorders (INR \> 1.25, aPTT \> 35 s, or platelet count \< 100,000/μL) * Reoperation (redo cardiac surgery) * Congestive heart failure * Chronic kidney failure * Sepsis * Hypoxia * Ocular trauma * Optic nerve pathology
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main aim of this study is to evaluate nutritional knowledge and adherence to the Mediterranean diet through the administration of questionnaires in patients with type 2 Diabetes Mellitus belonging to Outpatient Diabetology Service of the Hospital.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Other: administration of questionnaires - Collection of Clinical Parameters - Hand Grip Test — The acquisition of personal and clinical information and the data obtained from the questionnaires will be carried out in conjunction with the usual control visits planned as part of normal clinical practice

Primary Outcomes

  • Average Nutritional Knowledge Score (NK) (through study completion, an average of 1 year)
  • Mediterranean Diet Adherence (AMD) value (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-22
Completion: 2026-05-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Casa di Cura Dott. Pederzoli
Contact Information
Study Contact:
Maria Grazia Zenti, MD
+39 0456444193
urc@ospedalepederzoli.it
Ospedale P. Pederzoli Casa di Cura Privata S.p.A.
Interventions
  • Other: administration of questionnaires - Collection of Clinical Parameters - Hand Grip Test — The acquisition of personal and clinical information and the data obtained from the questionnaires will be carried out in conjunction with the usual control visits planned as part of normal clinical practice
Study Locations (1 sites)
Ospedale P. Pederzoli Casa di Cura Privata S.p.A., Peschiera del Garda, Verona 37019 Italy
Eligibility Criteria
Inclusion Criteria: * T2DM in nutritional and/or pharmacological euglycemic treatment (metformin, gliptins, gliflozines, incretin mimetics, pioglitazone) * Signing of informed consent Exclusion Criteria: * Patient with Diabetes Mellitus type 1 * Patients with insulin T2DM treated
Conditions Stage III Breast Cancer
Phase PHASE2
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the detection rate of distant metastases using \[18F\]FES PET/CT in patients with low-grade, ER-positive stage III breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Fluoroestradiol (18F) — Images for 90 minutes after F-18 FES injection

Primary Outcomes

  • Patient based detection rate of qualitative [18F]FES PET/CT evaluation for distant metastases (Baseline (index [18F]FES PET/CT image interpretation performed within 1 week after PET/CT acquisition, prior to initiation of definitive treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-24
Completion: 2029-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Asan Medical Center
Principal Investigators:
  • Hyehyun Jeong (PRINCIPAL_INVESTIGATOR) - Asan Medical Center
Contact Information
Study Contact:
Sangwon Han
+82-2-3010-0657
hswon87@amc.seoul.kr
Jaeeun Kim
+82-2-3010-4572
kje0216@amc.seoul.kr
Sangwon Han
+82-2-3010-0657
hswon87@amc.seoul.kr
Asan Medical Center
Interventions
  • Diagnostic Test: Fluoroestradiol (18F) — Images for 90 minutes after F-18 FES injection
Study Locations (1 sites)
Asan Medical Center, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: 1. Male or female patients aged ≥19 years, regardless of race/ethnicity 2. Patients newly diagnosed with invasive breast cancer within 90 days prior to screening, with documented histopathological confirmation. 3. Patients diagnosed with histologically confirmed estrogen receptor-positive, histologic grade 1 or 2 primary breast cancer 4. Patients with clinical stage IIIA-IIIC disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system 5. Patients who have undergone, or are scheduled to undergo chest computed tomography (CT), abdominal CT, and bone scintigraphy within 90 days prior to screening before the 18F-FES PET/CT scan 6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤2 Exclusion Criteria: * The subject or the subject's legally authorized representative has not signed the informed consent form * Subjects who are currently receiving systemic therapy for breast cancer (e.g., neoadjuvant chemotherapy, hormonal therapy) * Subjects with a history of another invasive malignancy within the past 2 years (except for non-melanoma skin cancer) * Subjects diagnosed with distant metastases on chest CT, abdominal CT, or bone scintigraphy performed within 90 days prior to screening or before the 18F-FES PET/CT scan * Subjects for whom neither biopsy nor ≥6 months of follow-up imaging has been performed for lesions suspicious for distant metastases * Pregnant or breastfeeding women. The following cases are considered not at risk of pregnancy: (1) physiologically postmenopausal (no menses for ≥2 years), (2) surgically sterile (history of bilateral oophorectomy or hysterectomy), (3) women of childbearing potential with a documented negative serum or urine pregnancy test within 24 hours prior to 18F-FES administration, and who agree to use effective contraception during the trial. * Subjects with serious and/or uncontrolled and/or unstable medical conditions (e.g., congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic kidney disease, or chronic liver disease) * Subjects who are relatives or students of the investigator, or otherwise in a dependent relationship with the investigator * Subjects who, in the judgment of the investigator, are unable to provide complete data for the clinical trial due to personal circumstances or other reasons
Conditions Depression Disorder, Anxiety, Mental Hea...
Phase NA
Enrollment 135
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Nuts have a high nutrient density, and numerous studies have reported their cardiometabolic benefits. Although observational studies in adults have indicated a potential link between nut consumption and improved mental health, there is still insufficient evidence from experimental studies to draw firm conclusions about this association.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: mixed nuts. Group A — Participants will be instructed to consume a single daily dose of nuts (30 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 moths). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer. Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected
  • Dietary Supplement: mixed nuts. Group B — Participants will be instructed to consume two daily doses of nuts (60 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 months). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer.Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected
  • Other: control group — Participants will be instructed to maintain their regular diet without any specific dietary instructions or intervention.

Primary Outcomes

  • Depression ("Day 0", "Month 3", "Month 6", "Month 12")
  • Anxiety ("Day 0", "Month 3", "Month 6", "Month 12")
  • Stress ("Day 0", "Month 3", "Month 6", "Month 12")
  • Episodic memory ("Day 0", "Month 3", "Month 6", "Month 12")
  • Working memory ("Day 0", "Month 3", "Month 6", "Month 12")
  • Cognitive flexibility ("Day 0", "Month 3", "Month 6", "Month 12")
  • Processing speed ("Day 0", "Month 3", "Month 6", "Month 12")
  • Inhibitory control and attention ("Day 0", "Month 3", "Month 6", "Month 12")
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-24
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 135 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Castilla-La Mancha
Collaborators: European Union
Principal Investigators:
  • Arthur Eumann Mesas, PhD (PRINCIPAL_INVESTIGATOR) - Health and Social Research Center
Contact Information
Study Contact:
Arthur Eumann Mesas, PdD
+34 926053716
arthur.emesas@uclm.es
Miriam Garrido-Miguel, PhD
+34 926054003
miriam.garrido@uclm.es
Arthur Eumann Mesas, PhD
+34 926053716
arthur.emesas@uclm.es
Health and Social Research Center. University of Castilla-La Mancha
Interventions
  • Dietary Supplement: mixed nuts. Group A — Participants will be instructed to consume a single daily dose of nuts (30 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 moths). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer. Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected
  • Dietary Supplement: mixed nuts. Group B — Participants will be instructed to consume two daily doses of nuts (60 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 months). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer.Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected
  • Other: control group — Participants will be instructed to maintain their regular diet without any specific dietary instructions or intervention.
Study Locations (1 sites)
Health and Social Research Center. University of Castilla-La Mancha, Cuenca, Cuenca 16071 Spain
Eligibility Criteria
Participants must meet all the following criteria to be considered eligible for selection and randomization: Inclusion Criteria: * Age: Participants must be between 18 and 25 years old. * Academic Status: Participants must be enrolled as university students. * Field of Study: Participants may come from any academic program offered at the Cuenca Campus, including Nursing, Social Work, Education, Fine Arts, Engineering, Journalism, and Teaching. Participants will be excluded from the study if they have any of the following conditions, based on self-reported information: Exclusion Criteria: * Allergies: Known nut allergy. * Self-reported cardiovascular, metabolic, gastrointestinal or mental health disorder.
Conditions Support, Postpartum Period, Parenting
Phase Not Applicable
Enrollment 193
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The transition to motherhood, particularly for first-time (primiparous) women, is a critical life period requiring substantial psychological and social adjustment. Hormonal changes, increased caregiving responsibilities, sleep disturbances, and potential social isolation during pregnancy and the postpartum period may increase vulnerability to stress, anxiety, and depressive symptoms. Postpartum depression (PPD) is a common mental health concern that adversely affects maternal well-being, mother-infant interaction, and infant development, with insufficient social support identified as one of its most significant risk factors. Maternal self-efficacy, defined as a mother's perceived competence in caring for and responding to her infant's needs, is a key indicator of successful adaptation to the parenting role. Evidence suggests that maternal self-efficacy develops primarily within the first months after childbirth and tends to be lower in primiparous women. Low parenting self-efficacy has been associated with increased depressive symptoms, higher parenting stress, impaired mother-infant bonding, and negative developmental outcomes for the infant. Among social support sources, partner support plays a particularly protective role during the transition to parenthood. Emotional, informational, and practical support provided by the partner has been shown to enhance maternal self-efficacy, reduce psychological distress, improve marital adjustment, and lower the risk of postpartum depression. Conversely, low perceived partner support and relationship difficulties are associated with an increased risk of PPD in primiparous mothers. The aim of this study is to examine the relationship between perceived partner support and postpartum parenting self-efficacy and depressive symptoms in primiparous women. Additionally, the study seeks to evaluate the explanatory and protective role of partner support on maternal self-efficacy and postpartum depression during the early postpartum period.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Primary Outcomes

  • Introduction Information Forum (At enrollment)
  • Parenting Self-Confidence (Karitane Parenting Confidence Scale) (At enrollment)
  • Perceived Spousal Support measured by the Early Postpartum Perceived Spousal Support Scale (At enrollment)
  • Postpartum Depression (Edinburgh Postnatal Depression Scale) (At enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-30
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 193 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul University - Cerrahpasa
Collaborators: Acibadem University
Principal Investigators:
  • Merve Coşkun, Ph.D. (PRINCIPAL_INVESTIGATOR) - Acibadem University
Contact Information
Study Contact:
Eslem Altıntaş, MSc
+90 541 610 54 12
eslem.altintas@acibadem.edu.tr
Eslem Altıntaş, MSc
Investigator
eslem.altintas@acibadem.edu.tr
Online study
Interventions
N/A
Study Locations (1 sites)
Online study, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusionsd Criteria: * Aged 18 years or older * Primiparous mothers (first childbirth) * Between 0 and 12 months postpartum * Living with spouse or partner * Able to read and write Turkish * Having access to the internet * Voluntarily agreeing to participate in the study Exclusion Criteria: * Diagnosed neurological disorder * Diagnosed psychiatric disorder * Visual impairment preventing completion of questionnaires * Cognitive impairment preventing completion of questionnaires
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to better understand how time restricted eating (eating all food in an 8 hour window) can help a person receiving chemotherapy treatment for breast cancer, stages I-IV. The aim is to find out if time restricted is feasible and acceptable to individuals starting chemotherapy for breast cancer. We will test 3 different eating window options compared to a control group for 24 weeks.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Time restricted eating — Participants assigned to this arm will follow the 8-h TRE protocol. Participants will consume food ad libitum (no calorie or food restrictions) during a self-selected 8-h eating window (beginning at 10:00 am, 11:00am, or 12:00 pm) and fasting for 16 hours daily. They will follow this same eating pattern for the length of the intervention. Calorie free drinks such as water, black coffee, and diet soda, are permitted during the fasting period. The eating window will allow for a typical breakfast/lunch/dinner eating pattern.

Primary Outcomes

  • Recruitment feasibility (24 weeks)
  • TRE Acceptibility (24 weeks)
  • TRE adherence (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2026-12-31
Eligibility
Age: 25 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Contact Information
Study Contact:
Kelsey Gabel, RD, PhD
312-413-8911
kdipma2@uic.edu
Kelsey Gabel, RD PhD
(312) 413-8911
fastlab@uic.edu
Robert H. Lurie Comprehensive Cancer Center
Kelsey Gabel, RD, PhD
312-413-8911
kdipma2@uic.edu
University of Illinois Chicago
Interventions
  • Behavioral: Time restricted eating — Participants assigned to this arm will follow the 8-h TRE protocol. Participants will consume food ad libitum (no calorie or food restrictions) during a self-selected 8-h eating window (beginning at 10:00 am, 11:00am, or 12:00 pm) and fasting for 16 hours daily. They will follow this same eating pattern for the length of the intervention. Calorie free drinks such as water, black coffee, and diet soda, are permitted during the fasting period. The eating window will allow for a typical breakfast/lunch/dinner eating pattern.
Study Locations (2 sites)
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611 United States
University of Illinois Chicago, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria: * Age 25-99 at time of consent * English language or Spanish language (based on availability of lab interpreters) * ECOG 0 or 1 * Breast cancer to meet histologically confirmed Stage I-III or Stage IV with Medical Oncology approval. * Demonstrates adequate organ function (absolute neutrophil count ≥ 1,500/μL). * All screening labs to be obtained within 30 days prior to registration. * Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. * Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. * As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: * Women with type 1 or insulin dependent type 2 diabetes * Women with BMI \> 45kg/m2 and \< 18.5 kg/m2 * Women who are pregnant or nursing. A negative serum or urine pregnancy test is required per institutional practice guidelines. * Shift workers * Women with a history of eating disorders * Enrolled participants with a significant weight loss or weight gain within 3 months of the study (weight gain or loss \>4kg) * Uncontrolled HIV/AIDS or active viral hepatitis * Any prior malignancy \<5 years, chemotherapy within the last year or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist. * Breast cancer recurrence classified by the treating medical oncologist * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial. * Other major comorbidity, as determined by study PI * Illicit drug use within previous 3 months or excessive use of alcohol (i.e., \> 2 drinks/day) * Currently participating in Weight Watcher's or another weight loss program, including weight loss medication such as GLP-1 medications. * Myocardial infarction * Congestive heart failure * Chronic hepatitis * Cirrhosis * Chronic pancreatitis * History of solid organ transplantation
Conditions Breast Cancer, Breast Surgery
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Robotic surgical systems provide notable advantages including enhanced dexterity, a magnified three-dimensional high-definition view, and high-resolution imaging, thereby improving operative stability and precision. These features make robotic systems particularly suitable for procedures performed within confined operative spaces. As the breast is a solid organ without a natural cavity, robotic systems demonstrate strong adaptability for breast surgery. Robot-assisted breast-conserving surgery (RABCS) is one of the currently utilized robotic techniques in clinical breast cancer surgery. However, as robotic breast surgery remains in its early stage of development, evidence regarding the clinical outcomes of RABCS remains limited in the literature. Therefore, this study compares the surgical outcomes of endoscopic breast-conserving surgery and robot-assisted breast-conserving surgery in breast cancer patients, aiming to assess and elucidate the clinical value of RABCS.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Robotic breast-conserving surgery — To perform breast-conserving surgery using a robotic system, thereby validating the safety and feasibility of robotic breast-conserving surgery.
  • Procedure: Endoscopic breast-conserving surgery — To perform breast-conserving surgery using a endoscopic system.

Primary Outcomes

  • Postoperative complication rate (1 month postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-27
Completion: 2026-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Contact Information
Study Contact:
Haiyan Li
+86 15813340604
lihy27@mail.sysu.edu.cn
Haiyan Li
+86 15813340604
lihy27@mail.sysu.edu.cn
the Sixth Affiliated Hospital of Sun Yat-sen University
Interventions
  • Procedure: Robotic breast-conserving surgery — To perform breast-conserving surgery using a robotic system, thereby validating the safety and feasibility of robotic breast-conserving surgery.
  • Procedure: Endoscopic breast-conserving surgery — To perform breast-conserving surgery using a endoscopic system.
Study Locations (1 sites)
the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 80 years * Pathologically confirmed breast cancer prior to surgery * Sufficient glandular volume with a tumor-to-breast volume ratio ≤20% * A unifocal lesion confined to the glandular tissue * Clear desire for breast conservation and willingness to undergo R-BCS or E-BCS * No evidence of distant metastasis, no involvement of the skin or chest wall * Eligibility for standard postoperative radiotherapy Exclusion Criteria: * The presence of diffuse suspicious lesions or microcalcifications for which wide local resection was unlikely to achieve adequate negative margins or satisfactory aesthetic outcomes * Bilateral breast cancer or inflammatory breast cancer * After neoadjuvant therapy, requirement for additional concurrent surgical procedures * Inability to tolerate general anesthesia or undergo surgery * Contraindications to radiotherapy or a history of prior chest wall irradiation, pregnancy- or lactation-associated breast cancer * Refuse to undergo R-BCS or E-BCS